Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

For this year’s ‘biotechs to watch’ selection, each Labiotech journalist picked five companies they believe will be worth following in 2026. Some earned their spot after clear momentum in 2025, while ...

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends ...